Other
Tauopathies
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Tauopathies is an early-stage landscape with 0 programs across 1 company. The most active players are Woolsey Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Unknown status1 · 25%
Terminated1 · 25%
Clinical Trials
Trial Activity
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Completed·—·Phase 1·NCT02103894·16 enrolled
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Completed·—·Phase 1·NCT02531360·7 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)